383,074 results on '"METASTASIS"'
Search Results
2. Systemic Administration of Cowpea Mosaic Virus Demonstrates Broad Protection Against Metastatic Cancers.
- Author
-
Chung, Young, Zhao, Zhongchao, Jung, Eunkyeong, Omole, Anthony, Wang, Hanyang, Sutorus, Lucas, and Steinmetz, Nicole
- Subjects
CPMV ,adjuvant therapy ,cancer ,metastasis ,Comovirus ,Animals ,Mice ,Female ,Neoplasm Metastasis ,Humans ,Cell Line ,Tumor ,Disease Models ,Animal - Abstract
The key challenge in cancer treatment is prevention of metastatic disease which is therapeutically resistant and carries poor prognoses necessitating efficacious prophylactic approaches that prevent metastasis and recurrence. It is previously demonstrated that cowpea mosaic virus (CPMV) induces durable antitumor responses when used in situ, i.e., intratumoral injection. As a new direction, it is showed that CPMV demonstrates widespread effectiveness as an immunoprophylactic agent - potent efficacy is demonstrated in four metastatic models of colon, ovarian, melanoma, and breast cancer. Systemic administration of CPMV stimulates the innate immune system, enabling attack of cancer cells; processing of the cancer cells and associated antigens leads to systemic, durable, and adaptive antitumor immunity. Overall, CPMV demonstrated broad efficacy as an immunoprophylactic agent in the rejection of metastatic cancer.
- Published
- 2024
3. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Published
- 2024
4. Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION)
- Author
-
Miami Cancer Institute and Cantex Pharmaceuticals Inc.
- Published
- 2024
5. Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
- Published
- 2024
6. Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
- Author
-
ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H., b.e.imaging GmbH, and Radboud University Medical Center
- Published
- 2024
7. Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors (CETUPANC)
- Published
- 2024
8. Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer
- Published
- 2024
9. EchoTip AcuCore Post-Market Clinical Study
- Published
- 2024
10. A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (HAMMER)
- Published
- 2024
11. ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
- Author
-
Genentech, Inc. and Oncoceutics, Inc.
- Published
- 2024
12. The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
- Author
-
Jiang, Xiaoyu, Wang, Yuli, Guo, Lulu, Wang, Yige, Miao, Tianshu, Ma, Lijuan, Wei, Qin, Lin, Xiaoyan, Mao, Jian-Hua, and Zhang, Pengju
- Subjects
Breast cancer ,Chemotherapy ,FAM83D ,FBXW7 ,Metastasis ,Ubiquitination and degradation ,Humans ,Female ,F-Box-WD Repeat-Containing Protein 7 ,Cell Cycle Proteins ,Cell Line ,Tumor ,Breast Neoplasms ,Prognosis ,Cell Proliferation ,Gene Expression Regulation ,Neoplastic ,Microtubule-Associated Proteins - Abstract
Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding sites on FAM83D led to that FAM83D lost its capability to promote the ubiquitination and proteasomal degradation of FBXW7; cell proliferation, migration, and invasion in vitro; and tumor growth and metastasis in vivo, indicating that the FBXW7-binding sites on FAM83D are essential for its oncogenic functions. A meta-evaluation of FAM83D revealed that the prognostic impact of FAM83D was independent on molecular subtypes. The higher expression of FAM83D has poorer prognosis. Moreover, high expression of FAM83D confers resistance to chemotherapy in BCs, which is experimentally validated in vitro. We conclude that identification of FBXW7-binding sites on FAM83D not only reveals the importance for FAM83D oncogenic function, but also provides valuable insights for drug target.
- Published
- 2024
13. Pathophysiological roles of thrombospondin-4 in disease development
- Author
-
Genaro, Karina and Luo, Z David
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Osteoporosis ,Aetiology ,2.1 Biological and endogenous factors ,Musculoskeletal ,Humans ,Thrombospondins ,Extracellular Matrix ,Cell Movement ,Morphogenesis ,Cardiovascular Diseases ,Thrombospondin-4 ,Calcium-binding ,Extracellular matrix glycoprotein ,Angiogenesis ,Inflammation ,Synaptogenesis ,Cardiovascular diseases ,Cancer growth ,Metastasis ,Nociception ,Paediatrics and Reproductive Medicine ,Developmental Biology ,Biochemistry and cell biology - Abstract
Thrombospondin-4 (TSP-4) belongs to the extracellular matrix glycoprotein family of thrombospondins (TSPs). The multidomain, pentameric structure of TSP-4 allows its interactions with numerous extracellular matrix components, proteins and signaling molecules that enable its modulation to various physiological and pathological processes. Characterization of TSP-4 expression under development and pathogenesis of disorders has yielded important insights into mechanisms underlying the unique role of TSP-4 in mediating various processes including cell-cell, cell-extracellular matrix interactions, cell migration, proliferation, tissue remodeling, angiogenesis, and synaptogenesis. Maladaptation of these processes in response to pathological insults and stress can accelerate the development of disorders including skeletal dysplasia, osteoporosis, degenerative joint disease, cardiovascular diseases, tumor progression/metastasis and neurological disorders. Overall, the diverse functions of TSP-4 suggest that it may be a potential marker or therapeutic target for prognosis, diagnosis, and treatment of various pathological conditions upon further investigations. This review article highlights recent findings on the role of TSP-4 in both physiological and pathological conditions with a focus on what sets it apart from other TSPs.
- Published
- 2024
14. Engrailed‐1 Promotes Pancreatic Cancer Metastasis
- Author
-
Xu, Jihao, Roe, Jae‐Seok, Lee, EunJung, Tonelli, Claudia, Ji, Keely Y, Younis, Omar W, Somervile, Tim DD, Yao, Melissa, Milazzo, Joseph P, Tiriac, Herve, Kolarzyk, Anna M, Lee, Esak, Grem, Jean L, Lazenby, Audrey J, Grunkemeyer, James A, Hollingsworth, Michael A, Grandgenett, Paul M, Borowsky, Alexander D, Park, Youngkyu, Vakoc, Christopher R, Tuveson, David A, and Hwang, Chang‐Il
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Pancreatic Cancer ,Genetics ,Rare Diseases ,Biotechnology ,Digestive Diseases ,Humans ,Transcription Factors ,Pancreatic Neoplasms ,Gene Expression Regulation ,Carcinoma ,Pancreatic Ductal ,apoptosis ,cancer progression ,cancer therapeutics ,developmental transcription factor ,Engrailed-1 ,epigenetic reprogramming ,ERK signaling ,metastasis ,pancreatic ductal adenocarcinoma - Abstract
Engrailed-1 (EN1) is a critical homeodomain transcription factor (TF) required for neuronal survival, and EN1 expression has been shown to promote aggressive forms of triple negative breast cancer. Here, it is reported that EN1 is aberrantly expressed in a subset of pancreatic ductal adenocarcinoma (PDA) patients with poor outcomes. EN1 predominantly repressed its target genes through direct binding to gene enhancers and promoters, implicating roles in the activation of MAPK pathways and the acquisition of mesenchymal cell properties. Gain- and loss-of-function experiments demonstrated that EN1 promoted PDA transformation and metastasis in vitro and in vivo. The findings nominate the targeting of EN1 and downstream pathways in aggressive PDA.
- Published
- 2024
15. Growth signaling autonomy in circulating tumor cells aids metastatic seeding
- Author
-
Sinha, Saptarshi, Farfel, Alex, Luker, Kathryn E, Parker, Barbara A, Yeung, Kay T, Luker, Gary D, and Ghosh, Pradipta
- Subjects
Biochemistry and Cell Biology ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Biological Sciences ,Breast Cancer ,Women's Health ,Cancer ,Genetics ,cellular autonomy ,GIV ,Girdin ,CCDC88A ,metastasis - Abstract
Self-sufficiency (autonomy) in growth signaling, the earliest recognized hallmark of cancer, is fueled by the tumor cell's ability to "secrete-and-sense" growth factors (GFs); this translates into cell survival and proliferation that is self-sustained by autocrine/paracrine secretion. A Golgi-localized circuitry comprised of two GTPase switches has recently been implicated in the orchestration of growth signaling autonomy. Using breast cancer cells that are either endowed or impaired (by gene editing) in their ability to assemble the circuitry for growth signaling autonomy, here we define the transcriptome, proteome, and phenome of such an autonomous state, and unravel its role during cancer progression. We show that autonomy is associated with enhanced molecular programs for stemness, proliferation, and epithelial-mesenchymal plasticity. Autonomy is both necessary and sufficient for anchorage-independent GF-restricted proliferation and resistance to anticancer drugs and is required for metastatic progression. Transcriptomic and proteomic studies show that autonomy is associated, with a surprising degree of specificity, with self-sustained epidermal growth factor receptor (EGFR)/ErbB signaling. Derivation of a gene expression signature for autonomy revealed that growth signaling autonomy is uniquely induced in circulating tumor cells (CTCs), the harshest phase in the life of tumor cells when it is deprived of biologically available epidermal growth factor (EGF). We also show that autonomy in CTCs tracks therapeutic response and prognosticates outcome. These data support a role for growth signaling autonomy in multiple processes essential for the blood-borne dissemination of human breast cancer.
- Published
- 2024
16. Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations
- Author
-
Habowski, Amber N, Budagavi, Deepthi P, Scherer, Sandra D, Aurora, Arin B, Caligiuri, Giuseppina, Flynn, William F, Langer, Ellen M, Brody, Jonathan R, Sears, Rosalie C, Foggetti, Giorgia, Estape, Anna Arnal, Nguyen, Don X, Politi, Katerina A, Shen, Xiling, Hsu, David S, Peehl, Donna M, Kurhanewicz, John, Sriram, Renuka, Suarez, Milagros, Xiao, Sophie, Du, Yuchen, Li, Xiao-Nan, Navone, Nora M, Labanca, Estefania, and Willey, Christopher D
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Biotechnology ,Cancer ,Good Health and Well Being ,patient derived models of cancer ,organoids ,mouse models ,sequencing ,tumor microenvironment ,tumor cells ,metastasis ,Oncology and carcinogenesis - Abstract
For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models of cancer (PDMCs) have more recently come to the forefront of preclinical cancer models and are even finding their way into clinical practice as part of functional precision medicine programs. The PDMC Consortium, supported by the Division of Cancer Biology in the National Cancer Institute of the National Institutes of Health, seeks to understand the biological principles that govern the various PDMC behaviors, particularly in response to perturbagens, such as cancer therapeutics. Based on collective experience from the consortium groups, we provide insight regarding PDMCs established both in vitro and in vivo, with a focus on practical matters related to developing and maintaining key cancer models through a series of vignettes. Although every model has the potential to offer valuable insights, the choice of the right model should be guided by the research question. However, recognizing the inherent constraints in each model is crucial. Our objective here is to delineate the strengths and limitations of each model as established by individual vignettes. Further advances in PDMCs and the development of novel model systems will enable us to better understand human biology and improve the study of human pathology in the lab.
- Published
- 2024
17. Game-changing insights on vertebral skeletal stem cells in bone metastasis and therapeutic horizons
- Author
-
CHEN, QIUQIANG, ZHAO, XIAOLEI, and MA, WENXUE
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Stem Cell Research - Nonembryonic - Human ,Stem Cell Research ,Stem Cell Research - Nonembryonic - Non-Human ,Cancer ,2.1 Biological and endogenous factors ,Aetiology ,Musculoskeletal ,Humans ,Bone Neoplasms ,Stem Cells ,Vertebral skeletal stem cells ,Stem cell research ,Metastasis ,Breast ,prostate ,and lung cancers ,Spinal metastasis ,Matthew Greenblatt ,Genetic expressions ,Medicinal & Biomolecular Chemistry ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
Greenblatt and his team have unveiled vertebral skeletal stem cells (vSSCs) as a critical player in the landscape of bone metastasis. This commentary delves into the transformative discoveries surrounding vSSCs, emphasizing their distinct role in bone metastasis compared to other stem cell lineages. We illuminate the unique properties and functions of vSSCs, which may account for the elevated susceptibility of vertebral bones to metastatic invasion. Furthermore, we explore the exciting therapeutic horizons opened by this newfound understanding. These include potential interventions targeting vSSCs, modulation of associated signaling pathways, and broader implications for the treatment and management of bone metastasis. By shedding light on these game-changing insights, we hope to pave the way for novel strategies that could revolutionize the prognosis and treatment landscape for cancer patients with metastatic bone disease.
- Published
- 2024
18. Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer
- Author
-
Elekta Limited and Kevin Albuquerque, Professor
- Published
- 2024
19. SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy (Superman)
- Published
- 2024
20. Pembrolizumab + Idelalisib for Lung Cancer Study (PIL)
- Author
-
Merck Sharp & Dohme LLC, Gilead Sciences, and Asha Nayak, Professor of Medicine
- Published
- 2024
21. Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
- Author
-
amy tiersten, Professor - Hematology Oncology
- Published
- 2024
22. Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy (TRANSMET)
- Published
- 2024
23. Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
- Author
-
Zhengfei Zhu, Professor
- Published
- 2024
24. Definitive Radiation for High-Risk Spine Metastases
- Author
-
The University of Texas Health Science Center at San Antonio and Kartik Mani, Assistant Professor of Medicine
- Published
- 2024
25. Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)
- Author
-
Servier and Florian Gebauer, Principal investigator
- Published
- 2024
26. Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
- Published
- 2024
27. Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)
- Published
- 2024
28. Cancer‐associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma.
- Author
-
Knuutila, Jaakko S., Riihilä, Pilvi, Nissinen, Liisa, Heiskanen, Lauri, Kallionpää, Roosa E., Pellinen, Teijo, and Kähäri, Veli‐Matti
- Subjects
SQUAMOUS cell carcinoma ,SKIN cancer ,PROGNOSIS ,PLATELET-derived growth factor ,METASTASIS ,FIBROBLASTS - Abstract
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer and the metastatic disease is associated with poor prognosis. Cancer‐associated fibroblasts (CAFs) promote progression of cancer, but their role in cSCC is largely unknown. We examined the potential of CAF markers in the assessment of metastasis risk and prognosis of primary cSCC. We utilized multiplexed fluorescence immunohistochemistry for profiling CAF landscape in metastatic and non‐metastatic primary human cSCCs, in metastases, and in premalignant epidermal lesions. Quantitative high‐resolution image analysis was performed with two separate panels of antibodies for CAF markers and results were correlated with clinical and histopathological parameters including disease‐specific mortality. Increased stromal expression of fibroblast activation protein (FAP), α‐smooth muscle actin, and secreted protein acidic and rich in cysteine (SPARC) were associated with progression to invasive cSCC. Elevation of FAP and platelet‐derived growth factor receptor‐β (PDGFRβ) expression was associated with metastasis risk of primary cSCCs. High expression of PDGFRβ and periostin correlated with poor prognosis. Multimarker combination defined CAF subset, PDGFRα−/PDGFRβ+/FAP+, was associated with invasion and metastasis, and independently predicted poor disease‐specific survival. These results identify high PDGFRβ expression alone and multimarker combination PDGFRα−/PDGFRβ+/FAP+ by CAFs as potential biomarkers for risk of metastasis and poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Two-stage surgery for large sacrococcygeal chordomas: How I do it.
- Author
-
Macni, C., Kaissar, F., Hardwigsen, J., Jaloux, C., Mayoly, A., Witters, M., Kachouh, N., and Fuentes, S.
- Subjects
- *
SACROCOCCYGEAL region , *CHORDOMA , *METASTASIS , *RECTUS abdominis muscles , *SURGICAL excision - Abstract
Sacrococcygeal chordoma is a malignant, slow-growing, and locally aggressive bone tumor. A wide surgical margin is recommended to prevent local recurrence and metastasis. This disease tends to cause massive defects when rectal resection and sacrectomy are required. Therefore, soft tissue reconstruction is required and a pedicled vertical rectus abdominis muscle flap (VRAM) is a viable option. Important anatomical landmarks, advantages and limitations are discussed and the procedure is described step by step. This case report presents a two-stage operation with an anterior rectal resection and VRAM flap harvest followed by a complementary posterior approach with sacrectomy and soft tissue reconstruction: approach and results. The wound completely healed in six weeks. Three years after surgery, no local recurrence or distal metastasis was detected. This two-stage strategy presents a viable and safe option for large sacrococcygeal chordomas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Myxopapillary Ependymoma Metastasis Mimicking Pulmonary Embolism: An Illustrative Case.
- Author
-
Fecker, Adeline, Maanum, Kayla A., Shahin, Maryam N., Hakar, Melanie, and Wright III, James M.
- Abstract
Myxopapillary ependymomas (MPEs) are rare spinal cord tumors with low rates of metastasis outside of the neuraxis. Gross total resection of MPEs can significantly improve progression-free survival; however, adjunctive treatment remains unstandardized. A 29-year-old female with a history of spina bifida occulta surgical correction and lower back pain presented with dyspnea and tachycardia. A large pulmonary artery mass was discovered consistent with pulmonary thromboembolism. It was subsequently determined to be an intravascular metastasis secondary to sacral MPE. Standardization of MPE treatment and clinical suspicion of spinal neoplasm in the setting of chronic back pain with undetermined origin are of value. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
- Author
-
Tanabe, Kenji, Kobayashi, Shuichiro, Maezawa, Yuya, Ishihara, Kensaku, Inoue, Naoki, Izumi, Keita, Fujiwara, Motohiro, Toide, Masahiro, Yamamoto, Takanobu, Uehara, Sho, Araki, Saori, Inoue, Masaharu, Takazawa, Ryoji, Numao, Noboru, Ohtsuka, Yukihiro, Tanaka, Hajime, Yoshida, Soichiro, and Fujii, Yasuhisa
- Abstract
Background: This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab. Methods: This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model. Results: During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both p < 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both p < 0.001), presence of visceral metastasis (both p < 0.001), and hemoglobin of < 9.2 g/dL (p = 0.030 and p = 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (p = 0.001). Conclusion: The GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Outcomes after Surgical Microwave Ablation for the Treatment of Colorectal Liver Metastasis.
- Author
-
Wells, Alexandra B., Butano, Vincent W., Phillips, Michael C., Mckillop, Iain H., Martinie, John B., Baker, Erin H., and Iannitti, David A.
- Subjects
- *
LIVER tumors , *PEARSON correlation (Statistics) , *ABLATION techniques , *CANCER relapse , *LOGISTIC regression analysis , *COLORECTAL cancer , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *CHI-squared test , *MANN Whitney U Test , *METASTASIS , *MEDICAL records , *ACQUISITION of data , *STATISTICS , *MICROWAVES , *CONFIDENCE intervals , *DATA analysis software , *OVERALL survival , *EVALUATION - Abstract
BACKGROUND: Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide. Of these, approximately 25% will have liver metastasis. We performed 394 microwave ablations (MWAs) and analyzed outcomes for survival and ablation failure. STUDY DESIGN: We conducted a retrospective review of patients who underwent a surgical MWA at a single-center high-volume institution from October 2006 to September 2022 using a prospectively maintained database. The primary outcome was overall survival. RESULTS: A total of 394 operations were performed on 328 patients with 842 tumors undergoing MWA. Median tumor size was 1.5 cm (range 0.4 to 7.0 cm), with the median number of tumors ablated per operation being 1 (range 1 to 11). A laparoscopic approach was used 77.9% of the time. Concomitant procedures were performed 63% of the time, most commonly hepatectomy (22.3%), cholecystectomy (17.5%), and colectomy (6.6%). Clavien-Dindo grade III or IV complication occurred in 12 patients (3.6%), and all of these patients had undergone concomitant procedures. Mortality within 30 days occurred in 4 patients (1.2%). The rate of incomplete ablation was 1.5% per tumor. Local recurrence occurred at a rate of 6.3% per tumor. Black patients were found to have a higher incidence of incomplete ablation and local recurrence. One-year survival probability was 91% (95% CI 87.9 to 94.3), with a mean overall survival of 57.6 months (95% CI 49.9 to 65.4 months). CONCLUSIONS: Surgical MWA offers a low-morbidity approach to treatment of colorectal liver metastasis, with low rate of failure. This large series reviews the outcomes of MWA as definitive treatment for colorectal liver metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy.
- Author
-
Yanagisawa, Takafumi, Kawada, Tatsushi, Bekku, Kensuke, Laukhtina, Ekaterina, Rajwa, Pawel, von Deimling, Markus, Chlosta, Marcin, Quhal, Fahad, Pradere, Benjamin, Karakiewicz, Pierre I., Mori, Keiichiro, Kimura, Takahiro, Shariat, Shahrokh F., and Schmidinger, Manuela
- Abstract
Objective: To compare the differential efficacy of first‐line immune checkpoint inhibitor (ICI)‐based combined therapies among patients with intermediate‐ and poor‐risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. Patients and Methods: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first‐line ICI‐based combined therapies. We performed network meta‐analysis (NMA) to compare the outcomes, including progression‐free survival (PFS) and objective response rates (ORRs), in patients with intermediate‐ and poor‐risk mRCC; we also assessed treatment‐related adverse events. Results: Overall, seven RCTs were included in the meta‐analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72–1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. Conclusions: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first‐line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker.
- Author
-
Kreis, Nina-Naomi, Moon, Ha Hyung, Wordeman, Linda, Louwen, Frank, Solbach, Christine, Yuan, Juping, and Ritter, Andreas
- Subjects
- *
TUMOR diagnosis , *RESEARCH funding , *CELL physiology , *TUMOR markers , *META-analysis , *CANCER patients , *SYSTEMATIC reviews , *GENE expression , *ONCOGENES , *CELL death , *KINESIN , *TUMORS , *PROGRESSION-free survival , *DISEASE progression , *GENOMES , *OVERALL survival ,TUMOR genetics - Abstract
KIF2C/MCAK (KIF2C) is the most well-characterized member of the kinesin-13 family, which is critical in the regulation of microtubule (MT) dynamics during mitosis, as well as interphase. This systematic review briefly describes the important structural elements of KIF2C, its regulation by multiple molecular mechanisms, and its broad cellular functions. Furthermore, it systematically summarizes its oncogenic potential in malignant progression and performs a meta-analysis of its prognostic value in cancer patients. KIF2C was shown to be involved in multiple crucial cellular processes including cell migration and invasion, DNA repair, senescence induction and immune modulation, which are all known to be critical during the development of malignant tumors. Indeed, an increasing number of publications indicate that KIF2C is aberrantly expressed in multiple cancer entities. Consequently, we have highlighted its involvement in at least five hallmarks of cancer, namely: genome instability, resisting cell death, activating invasion and metastasis, avoiding immune destruction and cellular senescence. This was followed by a systematic search of KIF2C/MCAK's expression in various malignant tumor entities and its correlation with clinicopathologic features. Available data were pooled into multiple weighted meta-analyses for the correlation between KIF2Chigh protein or gene expression and the overall survival in breast cancer, non-small cell lung cancer and hepatocellular carcinoma patients. Furthermore, high expression of KIF2C was correlated to disease-free survival of hepatocellular carcinoma. All meta-analyses showed poor prognosis for cancer patients with KIF2Chigh expression, associated with a decreased overall survival and reduced disease-free survival, indicating KIF2C's oncogenic potential in malignant progression and as a prognostic marker. This work delineated the promising research perspective of KIF2C with modern in vivo and in vitro technologies to further decipher the function of KIF2C in malignant tumor development and progression. This might help to establish KIF2C as a biomarker for the diagnosis or evaluation of at least three cancer entities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Gastroenteropankreatische neuroendokrine Neoplasien – Chirurgie im multimodalen Konzept.
- Author
-
Holzer, K. and Bartsch, D. K.
- Subjects
- *
LYMPHADENECTOMY , *LYMPHATIC metastasis , *BONE metastasis , *DRUG accessibility , *NEUROENDOCRINE tumors - Abstract
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are mainly found in the small intestine and pancreas. The course of the disease in patients is highly variable and depends on the degree of differentiation (G1–G3) of the neoplasm. The potential for metastasis formation of GEP-NEN is high even with good differentiation (G1). Lymph node metastases and, in many cases, liver metastases are also often found. Less common are bone metastases or peritoneal carcinomas. The treatment of these GEP-NENs is surgical, whenever possible. If an R0 resection with removal of all lymph node and liver metastases is successful, the prognosis of the patients is excellent. Patients with diffuse liver or bone metastases can no longer be cured by surgery alone. The long-term survival of these patients is nowadays possible due to the availability of drugs (e.g., somatostatin analogues, tyrosine kinase inhibitors), peptide receptor radionuclide therapy (PRRT) and liver-directed procedures, with a good quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Management of Parapharyngeal Metastatic Medullary Thyroid Carcinoma Via a Combined Trans-Cervical and Trans-Oral Robotic Approach.
- Author
-
Hyvrard, Clémentine, Couineau, Florent, Rigal, Tiffany, Louerat, Serena, Hans, Stéphane, and Baudouin, Robin
- Subjects
- *
NECK , *SURGICAL robots , *ANTIBIOTICS , *ADRENOCORTICAL hormones , *THYROID gland tumors , *SKULL base , *VOICE disorders , *MAGNETIC resonance imaging , *TREATMENT duration , *CALCITONIN , *METASTASIS , *SURGICAL complications , *THYROID gland , *CANCER cells , *PARALYSIS ,VOCAL cord diseases - Abstract
Introduction: Medullary thyroid carcinoma constitutes 5% to 10% of all thyroid cancers. Metastatic adenopathies may pose challenges in intricate anatomical locations, such as the parapharyngeal space. A rare case of metastatic medullary thyroid carcinoma in the parapharyngeal space has been treated in our unit using combined trans-cervical trans-oral robotic surgery. Our objective was to provide a detailed description of the surgery performed on this patient. Method: We reported a singular case report worth of interest. Result: A 42-year-old woman was addressed in our unit for the management of a medullary thyroid carcinoma adenopathy located in the right parapharyngeal space. A parapharyngeal 40.0 mm × 25.0 mm × 12.0 mm adenopathy was removed using a combined trans-cervical and trans-oral robotic approach without sacrifice or injury of vascular or nervous structure. Neither the tracheostomy nor the feeding tube was implemented. Feeding was resumed on postoperative day 1 and hospitalization spanned 7 days. Conclusion: An innovative combined trans-cervical and trans-oral robotic surgery approach was conducted to address a metastatic medullary thyroid carcinoma in the parapharyngeal space. This surgical technique allowed us to circumvent the need for a trans-mandibular approach, tracheostomy, and feeding tube and enabling successful tumor removal without fragmentation. Postoperative care was significantly eased. The sole complication observed was dysphonia, likely resulting from intra-operative stretching of the vagus nerve during the dissection of the carotid artery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Identification of prognostic imaging biomarkers in H3 K27-altered diffuse midline gliomas in adults: impact of tumor oxygenation imaging biomarkers on survival.
- Author
-
Sim, Yongsik, Choi, Kaeum, Han, Kyunghwa, Choi, Seo Hee, Lee, Narae, Park, Yae Won, Shin, Na-Young, Ahn, Sung Soo, Chang, Jong Hee, Kim, Se Hoon, and Lee, Seung-Koo
- Subjects
- *
GLIOMAS , *DIAGNOSTIC imaging , *RESEARCH funding , *BRAIN , *TUMOR markers , *RETROSPECTIVE studies , *MENINGEAL cancer , *DESCRIPTIVE statistics , *MAGNETIC resonance imaging , *CELL lines , *REACTIVE oxygen species , *OXYGEN in the body , *METASTASIS , *MEDICAL records , *ACQUISITION of data , *RESEARCH methodology , *SURVIVAL analysis (Biometry) , *BLOOD volume , *PHENOTYPES , *OVERALL survival , *ADULTS - Abstract
Purpose: To investigate prognostic markers for H3 K27-altered diffuse midline gliomas (DMGs) in adults with clinical, qualitative and quantitative imaging phenotypes, including tumor oxygenation characteristics. Methods: Retrospective chart and imaging reviews were conducted on 32 adults with H3 K27-altered DMGs between 2017 and 2023. Clinical and qualitative imaging characteristics were analyzed. Quantitative imaging assessment was performed from the tumor mask via automatic segmentation to calculate normalized cerebral blood volume (nCBV), capillary transit time heterogeneity (CTH), oxygen extraction fraction (OEF), relative cerebral metabolic rate of oxygen (rCMRO2), and mean ADC values. Leptomeningeal metastases (LM) was diagnosed with imaging. Cox analyses were conducted to determine predictors of overall survival (OS) in entire patients and a subgroup of patients with contrast-enhancing (CE) tumor. Results: The median patient age was 40.5 years (range 19.9–75.7), with an OS of 30.3 months (interquartile range 11.3–32.3). In entire patients, the presence of LM was the only independent predictor of OS (hazard ratio [HR] = 6.01, P = 0.009). In the subgroup of 23 (71.9%) patients with CE tumors, rCMRO2 of CE tumor (HR = 1.08, P = 0.019) and the presence of LM (HR = 5.92, P = 0.043) were independent predictors of OS. Conclusion: The presence of LM was independently associated with poor prognosis in adult patients with H3 K27-altered DMG. In patients with CE tumors, higher rCMRO2 of CE tumor, which may reflect higher metabolic activity in the tumor oxygenation microenvironment, may be a useful imaging biomarker to predict poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Pelvic lymph node involvement and risk of recurrence in HPV‐associated endocervical adenocarcinoma stage IA2‐IB1 according to Silva's system in two Colombian cancer centers.
- Author
-
Hernández, Jairo Alonso, Rodríguez, Juliana, Rendón, Gabriel, Trujillo, Lina Maria, Beltrán, María Islena, Mantilla, Carolina, Echeverry, Carolina, Mendoza, María Angélica, Gil, Mónica, Núñez, Marcela, Hernández, Marcela, Peralta, Jonathan, and Pareja, René
- Subjects
- *
HUMAN papillomavirus , *METASTASIS , *LYMPHATIC metastasis , *LYMPH nodes , *DISEASE relapse - Abstract
Objective: To compare the pelvic lymph node involvement and risk of recurrence in patients with human papillomavirus (HPV)‐associated endocervical adenocarcinoma stage IA2‐IB1 undergoing hysterectomy and/or trachelectomy plus lymphadenectomy, according to Silva's classification system. Methods: A retrospective cohort study was performed in two Colombian cancer centers. The cases were classified according to the Silva classification system. Clinical, surgical, and histopathological variables were evaluated. Recurrence risk was analyzed by patterns A, B, or C. A logistic regression model was performed for tumor recurrence. The Kaplan–Meier method was used to estimate overall survival and disease‐free survival (DFS). A weighted kappa was performed to determine the degree of concordance between pathologists. Results: A total of 100 patients were identified, 33% pattern A, 29% pattern B, and 38% pattern C. The median follow‐up time was 42.5 months. No evidence of lymph node involvement was found in patients classified as A and B, while in the C pattern was observed in 15.8% (n = 6) of cases (P < 0.01). There were 7% of cases with recurrent disease, of which 71.5% corresponded to type C pattern. Patients with Silva pattern B and C had 1.22‐ and 4.46‐fold increased risk of relapse, respectively, compared with pattern A. The 5‐year DFS values by group were 100%, 96.1%, and 80.3% for patterns A, B, and C, respectively. Conclusion: For patients with early‐stage HPV‐associated endocervical adenocarcinoma, the type C pattern presented more lymph node involvement and risk of recurrence compared to the A and B patterns. The concordance in diagnosis of different Silva's patterns by independents pathologists were good. Synopsis: Patients with HPV‐associated endocervical adenocarcinoma pattern Silva C have more lymph node involvement and recurrence risk; the best oncologic outcomes are for patterns A and B. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer.
- Author
-
Li, Peiyuan, Zhang, Huan, Chen, Tao, Zhou, Yajing, Yang, Jiaoyang, and Zhou, Jin
- Subjects
- *
EXTRACELLULAR matrix , *STOMACH cancer , *CANCER cells , *METASTASIS , *TUMOR microenvironment - Abstract
• Fibroblasts can be activated as cancer-associated fibroblasts in the tumourmicroenvironment. • Cancer-associated fibroblasts help promote gastric cancer metastasis. • Cancer-Associated Fibroblasts Form Signalling Network with Gastric Cancer Cells. • Multiple drugs targeting cancer-associated fibroblasts have been found to inhibit gastric cancer progression. Despite advances in surgery, radiotherapy and immunotherapy, the mortality rate for gastric cancer remains one of the highest in the world. A large body of evidence has demonstrated that cancer-associated fibroblasts (CAFs), as core members of the stroma, can secrete cytokines, proteins and exosomes to create a tumour microenvironment that is conducive to cancer cell survival. CAFs can also interact with cancer cells to form a complex signalling network, enabling cancer cells to more easily metastasise to other organs and tissues in the body and develop metastatic foci. In this review, we provide an overview of the CAFs concept and activators. We focus on elucidating their effects on immune cells, intratumoural vasculature, extracellular matrix, as well as cancer cell activity, metastatic power and metabolism, and on enhancing the metastatic ability of cancer cells through activation of JAK/STAT, NF/κB and CXCL12/CXCR4. Various therapeutic agents targeting CAFs are also under development and are expected to improve the prognosis of gastric cancer in combination with existing treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Delays between Uveal Melanoma Diagnosis and Treatment Increase the Risk of Metastatic Death.
- Author
-
Stålhammar, Gustav
- Subjects
- *
CILIARY body , *TUMOR diagnosis , *TREATMENT delay (Medicine) , *OPTIC disc , *MELANOMA diagnosis , *UVEA cancer - Abstract
To investigate if the interval between diagnosis and treatment of posterior uveal melanoma (UM) is associated with metastatic death. Retrospective, single-center cohort study. A total of 1145 patients consecutively diagnosed with posterior UM at St. Erik Eye Hospital, Stockholm, Sweden, from 2012 to 2022, with recorded dates of diagnosis and primary treatment. This cohort represents 81% of all diagnosed patients in Sweden during this period. Data on the interval between diagnosis and treatment were collected for all patients. Its prognostic importance was examined with univariate and multivariate competing risks regressions, and cumulative incidence analyses. Incidence of metastatic death (UM mortality) for patients with prompt (< 1 month from diagnosis) versus delayed treatment (≥ 1 month) and subdistribution hazard ratios (exp(β j)) for every additional 10-day delay in treatment. The mean interval between diagnosis and treatment was 34 days (SD, 56, range, 0–932). Patients treated promptly had larger tumors at diagnosis, but there were no differences in patient age, tumor distance to the optic disc, rates of ciliary body involvement (CBI) or extraocular extension (EXE), or symptom duration before diagnosis. Those who were treated more than 1 month after diagnosis had greater UM mortality in American Joint Committee on Cancer (AJCC) stage II and III. In stage I, UM mortality for delayed treatment was lower for the first 10 years, followed by a marked spike in the 11th year. In multivariate competing risks regressions of all 1145 patients with tumor diameter, thickness, CBI, and EXE as covariates, the risk for UM mortality increased with 1% for every additional 10-day delay in treatment (exp(β j) 1.01). Among 355 patients treated with enucleation, this delay was associated with UM mortality, independent of AJCC stage, cytomorphology, and level of immunohistochemical BAP-1 expression. Increasing time between diagnosis and treatment of UM is associated with a higher risk of metastatic death. These results challenge a central concept in the understanding of metastatic progression and may indicate the existence of late metastatic seeding. They also underscore the importance of prompt treatment. Validation in independent cohorts is recommended. The author(s) have no proprietary or commercial interest in any materials discussed in this article. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Cytologic features of mesenchymal, melanocytic and haematolymphoid tumours of the central nervous system and metastases.
- Author
-
Bárcena, Carmen and Jiménez‐Heffernan, José A.
- Subjects
- *
CENTRAL nervous system , *BRAIN tumors , *CELL differentiation , *HISTOGENESIS , *METASTASIS - Abstract
The current World Health Organization (WHO) classification of central nervous system (CNS) tumours includes several neoplasms that, while occurring in this location, are more frequently seen extracranially. These include mesenchymal, melanocytic and haematolymphoid neoplasms, as well as metastases. A few of these entities are exclusive of the CNS and have no extracranial counterpart. Despite their diverse histogenesis, these neoplasms share a peculiar predilection for involving meningeal structures. In fact, in the context of an intraoperative pathologic consultation of a meningeal tumour, virtually all these entities should be considered as potential diagnoses. Metastases in the CNS are very common. Most are carcinomas that cytologically resemble their site of origin. Loss of differentiation with cell dissociation and anaplasia and presence of accompanying fibrillary brain parenchyma can be a source of diagnostic problems. In this review, we intend to show the most relevant cytologic features of these tumours, and it is especially aimed at their analysis during intraoperative studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Meta-analysis of survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis: a promising, albeit infrequent, approach.
- Author
-
Hajibandeh, Shahin, Hajibandeh, Shahab, Sutcliffe, Robert P., and Bartlett, David
- Subjects
- *
PANCREATIC cancer , *ADJUVANT chemotherapy , *METASTASIS , *PANCREATIC surgery , *SURVIVAL rate , *PANCREATECTOMY , *PNEUMONECTOMY - Abstract
To evaluate survival outcomes of pulmonary resection for isolated metachronous pancreatic cancer metastasis. A systematic search of electronic data sources and reference lists were conducted. Proportion meta-analysis model was constructed to quantify 1- to 5-year survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis. Random-effects modelling was applied to calculate pooled outcome data. Twenty-four retrospective studies were included reporting a total of 168 patients who underwent pulmonary resection for isolated pancreatic cancer metastasis. The nature of the index pancreatic surgery included 65% pancreaticoduodenectomies, 17.5% distal pancreatectomies, 0.5% total pancreatectomy, and 17% unspecified. Adjuvant chemotherapy was given to 88% of the patients. The median disease-free interval was 35 (8–96) months. The type of pulmonary resection included 54% wedge resections, 26% lobectomies, 4% segmentectomies, 1% pneumonectomies, and 15% unspecified. Pulmonary resection was associated with 1-year survival of 91.1% (95% CI 86.6%–95.5%), 2-year survival of 77.5% (95% CI 68.9%–86.0%), 3-year survival of 65.0% (95% CI 50.7%–79.3%), 4-year survival of 52.0% (95% CI 37.2%–66.9%), and 5-year survival of 37.0% (95% CI 25.0%–49.1%). Pulmonary resection for isolated pancreatic cancer metastasis is associated with acceptable overall patient survival. We recommend selective pulmonary resection for isolated pulmonary metastasis from pancreatic cancer. Our findings may encourage conduction of better-quality studies in this context to help establishment of definitive treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer.
- Author
-
Pan, Meiyu, Lin, Yan, Liu, Yinhui, Xu, Ruijuan, and Yang, Jin
- Subjects
- *
BREAST cancer prognosis , *THERAPEUTIC use of antineoplastic agents , *HORMONE receptor positive breast cancer , *PATIENT safety , *ANTINEOPLASTIC agents , *META-analysis , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *METASTASIS , *SYSTEMATIC reviews , *DRUG efficacy , *MTOR inhibitors , *PHOSPHOTRANSFERASES , *PROGRESSION-free survival , *CYCLIN-dependent kinases , *CHEMICAL inhibitors - Abstract
Purpose: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2− metastatic breast cancer. Methods: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3–4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. Results: This study included 44 arms from 48 publications, with a total sample size of 7881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and an ORR of 40%, whereas PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and an ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and specific endocrine therapy used in combination significantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. Conclusion: Our study provides solid quantitative evidence for the first-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2− metastatic breast cancer in clinical guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Survival outcomes in head and neck squamous cell carcinoma of unknown primary: A national cohort study.
- Author
-
Hardman, John C., Constable, James, Dobbs, Sian, Hogan, Christopher, Hulse, Kate, Khosla, Shivun, Milinis, Kristijonas, Tudor‐Green, Ben, Williamson, Andrew, Paleri, Vinidh, Asimakopoulos, Panagiotis, Cooper, Fergus, Rao, Prerana, Davies, Katharine, Davies, Timothy, Derbyshire, Stephen, Gao, Chuanyu, Ike, Chiugo, Abdelkader, Maged, and Spraggs, Paul
- Subjects
- *
HUMAN papillomavirus , *SQUAMOUS cell carcinoma , *SURVIVAL rate , *OVERALL survival , *METASTASIS - Abstract
Introduction: To investigate factors influencing survival in head and neck squamous cell carcinoma of unknown primary (HNSCCUP). Methods: A retrospective observational cohort study was conducted, over 5 years from January 2015, in UK Head and Neck centres, of consecutive adults undergoing 18F‐Fluorodeoxyglucose‐PET‐CT within 3 months of diagnosis with metastatic cervical squamous cell carcinoma. Patients treated as HNSCCUP underwent survival analysis, stratified by neck dissection and/or radiotherapy to the ipsilateral neck, and by HPV status. Results: Data were received from 57 centres for 965 patients, of whom 482 started treatment for HNSCCUP (65.7% HPV‐positive, n = 282/429). Five‐year overall survival (OS) for HPV‐positive patients was 85.0% (95% CI 78.4–92.3) and 43.5% (95% CI 32.9–57.5) for HPV‐negative. HPV‐negative status was associated with worse OS, disease‐free (DFS), and disease‐specific (DSS) survival (all p <.0001 on log‐rank test) but not local control (LC) (p =.16). Unilateral HPV‐positive disease treated with surgery alone was associated with significantly worse DFS (p <.0001) and LC (p <.0001) compared to radiotherapy alone or combined modalities (5‐year DFS: 24.9%, 82.3% and 94.3%; 5‐year LC: 41.8%, 98.8% and 98.6%). OS was not significantly different (p =.16). Unilateral HPV‐negative disease treated with surgery alone was associated with significantly worse LC (p =.017) (5‐year LC: estimate unavailable, 93.3% and 96.6%, respectively). Small numbers with bilateral disease precluded meaningful sub‐group analysis. Conclusions: HPV status is associated with variable management and outcomes in HNSCCUP. Unilateral neck disease is treated variably and associated with poorer outcomes when managed with surgery alone. The impact of diagnostic oropharyngeal surgery on primary site emergence, survival and functional outcomes is unestablished. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. The role of non‐oropharyngeal biopsies in head and neck squamous cell carcinoma of unknown primary: A systematic review.
- Author
-
Bowe, C. M. and Garg, M.
- Subjects
- *
SQUAMOUS cell carcinoma , *SURVIVAL rate , *LYMPH nodes , *METASTASIS , *NASOPHARYNX - Abstract
Introduction: This systematic review aims to evaluate the role of biopsies in non‐oropharyngeal subsites in patients with cervical metastasis from head and neck squamous cell carcinoma of unknown primary (HNSCCUP). Methods: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Articles that encompassed non‐oropharyngeal biopsies in HNSCCUP as part of the diagnostic work‐up were selected and analysed. Results: A comprehensive search strategy was used to search relevant literature in PubMed from inception to October 2021. Eleven articles out of 860 were included, comprising 990 patients. There are no randomised control trials comparing the outcomes of survival and or locoregional control between patients who have or have not undergone non‐targeted biopsies of non‐oropharyngeal sub‐sites for HNSCCUP. Several retrospective studies which showed an extremely low yield from random biopsies (range of yield, 0%–9%) of non‐oropharyngeal subsites. Even targeted biopsies showed a low yield (range of yield, 0.6%–16.6%) from non‐oropharyngeal subsites. The primary site identified for Epstein–Barr virus (EBV) positive cervical lymph nodes with an unknown primary is mainly the nasopharynx (51.7%). Narrow band imaging (NBI) (sensitivity range, 64%–91%) helps in the detection of primaries to target biopsies in non‐oropharyngeal subsites. Conclusions: On the basis of this systematic review, it is not appropriate to offer biopsies of clinically and radiologically normal upper aerodigestive tract mucosa at non‐oropharyngeal sites. Offer nasopharyngeal biopsies when the cervical node sampling reveals EBV‐positive metastasis. Where available, NBI should be used to help detect and target biopsies in non‐oropharyngeal subsites. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it.
- Author
-
Lecouvet, Frederic E., Chabot, Caroline, Taihi, Lokmane, Kirchgesner, Thomas, Triqueneaux, Perrine, and Malghem, Jacques
- Subjects
- *
RADIONUCLIDE imaging , *BONE cancer , *MAGNETIC resonance imaging , *MEDICAL screening , *OSTEOSARCOMA , *LIPOSARCOMA - Abstract
Metastatic disease and myeloma present unique diagnostic challenges due to their multifocal nature. Accurate detection and staging are critical for determining appropriate treatment. Bone scintigraphy, skeletal radiographs and CT have long been the mainstay for the assessment of these diseases, but have limitations, including reduced sensitivity and radiation exposure. Whole-body MRI has emerged as a highly sensitive and radiation-free alternative imaging modality. Initially developed for skeletal screening, it has extended tumor screening to all organs, providing morphological and physiological information on tumor tissue. Along with PET/CT, whole-body MRI is now accepted for staging and response assessment in many malignancies. It is the first choice in an ever increasing number of cancers (such as myeloma, lobular breast cancer, advanced prostate cancer, myxoid liposarcoma, bone sarcoma, ...). It has also been validated as the method of choice for cancer screening in patients with a predisposition to cancer and for staging cancers observed during pregnancy. The current and future challenges for WB-MRI are its availability facing this number of indications, and its acceptance by patients, radiologists and health authorities. Guidelines have been developed to optimize image acquisition and reading, assessment of lesion response to treatment, and to adapt examination designs to specific cancers. The implementation of 3D acquisition, Dixon method, and deep learning-based image optimization further improve the diagnostic performance of the technique and reduce examination durations. Whole-body MRI screening is feasible in less than 30 min. This article reviews validated indications, recent developments, growing acceptance, and future perspectives of whole-body MRI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. The role of imaging in extremity sarcoma surgery.
- Author
-
Kantzos, Andrew J., Fayad, Laura M., Abiad, Jad El, Ahlawat, Shivani, Sabharwal, Samir, Vaynrub, Max, and Morris, Carol D.
- Subjects
- *
CROSS-sectional imaging , *ULTRASONIC imaging , *SARCOMA , *MAGNETIC resonance imaging , *DIAGNOSIS , *LIMB salvage - Abstract
The surgical management of extremity bone and soft tissue sarcomas has evolved significantly over the last 50 years. The introduction and refinement of high-resolution cross-sectional imaging has allowed accurate assessment of anatomy and tumor extent, and in the current era more than 90% of patients can successfully undergo limb-salvage surgery. Advances in imaging have also revolutionized the clinician's ability to assess treatment response, detect metastatic disease, and perform intraoperative surgical navigation. This review summarizes the broad and essential role radiology plays in caring for sarcoma patients from diagnosis to post-treatment surveillance. Present evidence-based imaging paradigms are highlighted along with key future directions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial.
- Author
-
Patel, P.H., Dreibe, S., Reid, A., Parker, C., Murray, J., Pathmanathan, A., Tirona, A., Guevara, J., Suh, Y.-E., Frew, J., Palaniappan, N., Syndikus, I., Attard, G., Tunariu, N., and Tree, A.C.
- Subjects
- *
CASTRATION-resistant prostate cancer , *ANTIANDROGENS , *DRUG toxicity , *BONES , *LYMPH nodes , *ABIRATERONE acetate , *RADIOTHERAPY , *DRUG side effects , *VISUAL analog scale , *QUESTIONNAIRES , *CLINICAL trials , *LUNGS , *DESCRIPTIVE statistics , *METASTASIS , *PRE-tests & post-tests , *LONGITUDINAL method , *QUALITY of life , *RADIATION doses , *HEALTH outcome assessment , *PROGRESSION-free survival , *DISEASE progression - Abstract
To assess toxicity and patient quality of life after stereotactic body radiotherapy (SBRT) to oligoprogressive disease (OPD) in patients with metastatic castrate-resistant prostate cancer (CRPC) on androgen receptor targeted agents (ARTA). This phase II trial enrolled patients with metastatic CRPC with ≤ 2 oligoprogressive lesions in bone, lymph node, lung, or prostate. All patients were receiving systemic treatment with abiraterone or enzalutamide at the time of oligoprogression. All patients received SBRT to the OPD site(s) and continued the current ARTA. Patients received 30 Gy in 5 fractions (alternate days) to the OPD site. The primary endpoint of the trial is to assess if SBRT to OPD sites results in progression free survival of >6 months. The primary endpoint for this toxicity analysis is the rate of grade 3 or higher adverse events at any timepoint up to 6 months after SBRT. Secondary endpoints included comparing pre- and post-SBRT patient-related outcomes reported using visual analogue scale scores and EQ-5D health questionnaire. Forty enrolled patients had at least 6 months of follow-up at the time of analysis. Grade 3 or higher toxicity from any cause recorded using common terminology criteria for adverse events and radiation therapy oncology group was found in 8/40 (20%) of patients, but only 1/40 (2.5%) was deemed possibly related to SBRT. There was no significant difference in mean EQ5D visual analogue scale score from baseline to each timepoint after SBRT (p = 0.449). In this prospective phase II clinical trial for OPD whilst on ARTA in the CRPC setting, we report low grade ≥ 3 toxicity after SBRT. There is no discernible change in patient-reported quality of life due to SBRT treatment. The final results of progression-free survival and toxicity of SBRT treatment will be reported once further follow-up is complete. • Stereotactic radiotherapy to oligoprogressive disease in metastatic prostate cancer patients on targeted agents is feasible. • Stereotactic body radiotherapy is well tolerated in patients with castrate-resistant prostate cancer. • There is minimal treatment-related effect on quality of life and patient-reported outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Bioelectric pharmacology of cancer: A systematic review of ion channel drugs affecting the cancer phenotype.
- Author
-
Kofman, Karina and Levin, Michael
- Subjects
- *
VOLTAGE-gated ion channels , *ION channels , *LIGAND-gated ion channels , *EVOLUTIONARY developmental biology , *PHARMACOLOGY , *CARCINOGENS , *ANTINEOPLASTIC agents - Abstract
Cancer is a pernicious and pressing medical problem; moreover, it is a failure of multicellular morphogenesis that sheds much light on evolutionary developmental biology. Numerous classes of pharmacological agents have been considered as cancer therapeutics and evaluated as potential carcinogenic agents; however, these are spread throughout the primary literature. Here, we briefly review recent work on ion channel drugs as promising anti-cancer treatments and present a systematic review of the known cancer-relevant effects of 109 drugs targeting ion channels. The roles of ion channels in cancer are consistent with the importance of bioelectrical parameters in cell regulation and with the functions of bioelectric signaling in morphogenetic signals that act as cancer suppressors. We find that compounds that are well-known for having targets in the nervous system, such as voltage-gated ion channels, ligand-gated ion channels, proton pumps, and gap junctions are especially relevant to cancer. Our review suggests further opportunities for the repurposing of numerous promising candidates in the field of cancer electroceuticals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review).
- Author
-
RAINA, RITU, BHATT, RAVINDER, and HUSSAIN, ARIF
- Subjects
- *
CELL cycle , *NATURAL products , *CARCINOGENESIS , *CANCER invasiveness , *ANTINEOPLASTIC agents - Abstract
One of the most extensively used herbal medicines is chrysin, a naturally occurring flavone commonly detected in several natural products, including propolis and honey. Due to its various biological properties, such as antioxidant, anti-estrogenic, anti-inflammatory, anti-allergic, antibacterial and anticancer activities, chrysin has emerged as the leading contender for health benefits. Amongst the several pharmacological effects exhibited by chrysin, its anticancer activity is the most attractive. Several studies have demonstrated that chrysin suppresses tumor progression in cell lines and animal models by inducing apoptosis, disrupting the cell cycle and inhibiting migration without generating toxicity or undesired side-effects in normal cells. Furthermore, chrysin also inhibits multi-drug resistant proteins and is effective in combination therapy. The present review comprehensively discusses the research developments in the understanding of the potential of chrysin as a potent anticancer agent achieved by modulating various cell targets and signaling pathways involved in inflammation, cell survival, apoptosis, growth, angiogenesis, invasion and metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.